Maxcyte (MXCT) Fundamental Analysis: Revenue, Earnings & Valuation

2.29 / 10

Underperform

Fundamental analysis rates MXCT as Underperform with a 2.3/10 score. Revenue‑MV and Profit‑MV provide slight support, but Fixed‑Asset turnover and zero income‑tax ratio drag performance. Overall, the company shows challenging financial health and limited growth prospects.

Analysis Checks(5/10)

Revenue-MV

Value-1.53

Score2/3

Weight30.07%

1M Return8.05%

Inventory turnover ratio

Value0.56

Score2/3

Weight-1.58%

1M Return-0.56%

Gross profit margin (%)

Value82.07

Score0/3

Weight-12.47%

1M Return-5.42%

Profit-MV

Value0.41

Score2/3

Weight24.47%

1M Return6.36%

Income tax / Total profit (%)

Value0.00

Score1/3

Weight0.60%

1M Return0.21%

Current assets turnover ratio

Value0.17

Score1/3

Weight-0.53%

1M Return-0.17%

Fixed assets turnover ratio

Value0.85

Score1/3

Weight-3.18%

1M Return-1.13%

Cost of sales ratio (%)

Value17.93

Score2/3

Weight-10.03%

1M Return-3.62%

Asset-MV

Value-0.48

Score1/3

Weight48.68%

1M Return11.48%

Cash-MV

Value-0.09

Score2/3

Weight23.98%

1M Return6.19%

Is MXCT undervalued or overvalued?

MXCT scores 2.29/10 on fundamentals and holds a Premium valuation at present. Backed by its -18.13% ROE, -132.57% net margin, -1.76 P/E ratio, 0.44 P/B ratio, and -26.47% earnings growth, these metrics solidify its Underperform investment rating.